Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 35003
Conférences

le (31m42s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Insights from DOSE and gaps in evidence with diuretic therapy (Alice MASCETTE)

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012NOVEL DIURETIC STRATEGIES IN HEART FAILUREChairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITAWebcast: Patrick ROSSIGNOL, Nancy, FRA➢ Clinical congestion due to volume overload is the main cause of hospitalization for patients with HF and is an important therapeutic target. Failure to achieve effective and rapid correction of this condition in many patients hospitalized for HF results in prolongation of hospital stay and unfavorable after-discharge outcome.➢ Loop diuretics, though often effective for treating congestion, have significant limitations. Discovering ways to optimize exposure to loop diuretics, achieving effective decongestion while protecting ...
Voir la vidéo
Conférences

le (51m35s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Ultrafiltration for acute cardiorenal syndrome in heart failure (Gian Paolo ROSSI)

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012NOVEL DIURETIC STRATEGIES IN HEART FAILUREChairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITAWebcast: Patrick ROSSIGNOL, Nancy, FRA➢ Clinical congestion due to volume overload is the main cause of hospitalization for patients with HF and is an important therapeutic target. Failure to achieve effective and rapid correction of this condition in many patients hospitalized for HF results in prolongation of hospital stay and unfavorable after-discharge outcome.➢ Loop diuretics, though often effective for treating congestion, have significant limitations. Discovering ways to optimize exposure to loop diuretics, achieving effective decongestion while protecting ...
Voir la vidéo
Conférences

le (12m14s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST (William T. ABRAHAM)

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012NOVEL DIURETIC STRATEGIES IN HEART FAILUREChairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITAWebcast: Patrick ROSSIGNOL, Nancy, FRA➢ Clinical congestion due to volume overload is the main cause of hospitalization for patients with HF and is an important therapeutic target. Failure to achieve effective and rapid correction of this condition in many patients hospitalized for HF results in prolongation of hospital stay and unfavorable after-discharge outcome.➢ Loop diuretics, though often effective for treating congestion, have significant limitations. Discovering ways to optimize exposure to loop diuretics, achieving effective decongestion while protecting ...
Voir la vidéo
Conférences

le (12m13s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST (Michael FELKER)

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012NOVEL DIURETIC STRATEGIES IN HEART FAILUREChairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITAWebcast: Patrick ROSSIGNOL, Nancy, FRA➢ Clinical congestion due to volume overload is the main cause of hospitalization for patients with HF and is an important therapeutic target. Failure to achieve effective and rapid correction of this condition in many patients hospitalized for HF results in prolongation of hospital stay and unfavorable after-discharge outcome.➢ Loop diuretics, though often effective for treating congestion, have significant limitations. Discovering ways to optimize exposure to loop diuretics, achieving effective decongestion while protecting ...
Voir la vidéo
Conférences

le (0s)

Atelier Restaurer un film, animé par les Equipes de la Cinémathèque française et des Archives françaises du Film du CNC

Animé par des spécialistes de la conservation et de la restauration, cet atelier propose une découverte et une sensibilisation aux techniques de sauvegarde et de restauration des films. Comment analyser les éléments de départ, évaluer les travaux à réaliser, choisir les méthodes les plus appropriées ? Des projections comparées et commentées permettront de mieux appréhender ces questions complexes, concernées en premier lieu par la révolution numérique.
Voir la vidéo
Label UNT Documentaires

le (2m22s)

Laginophrys vaginicola, épizoïte des crustacés

Logé dans une lorica de 50 à 80 microns, elle-même collée sur la carapace des crustacés tels que les ostracodes, Laginophrys profite des déplacements de ces derniers pour se nourrir. La couronne ciliaire, par ses mouvements semblables à ceux d'une vorticelle, crée un flux qui apporte les particules alimentaires. En cas de stress, l'animal se rétracte précipitamment dans sa lorica, puis ressort lentement, déployant à nouveau sa couronne ciliaire.
Voir la vidéo
Label UNT Documentaires

le (1m57s)

Herpetocypris reptans,crustacé ostracode

En fond noir, ce petit crustacé ostracode montre une carapace blanc nacré. Cette carapace est bivalve et ouverte ventralement d'où sortent les extrémités des appendices. Les mouvements de "balayage" de la cavité  par les appendices se voient par transparence. La pigmentation de l'oeil tranche sur l'opalescence bleuâtre de la carapace. Herpetocypris appartient au groupe des ostracodes marcheurs qui se déplacent dans le feutrage végétal de la mare.
Voir la vidéo
Conférences

le (7m14s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Angeles ALONSO)

MODIGLIANI Workshop 1 - Friday November 30, 2012 :THE THROMBOSIS TRIALISTS WORKSHOPDOSE AND TARGET PATIENT POPULATIONS ISSUESChairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN, Bucharest, ROMWebcast: Johanne SILVAIN, Paris, FRAThe development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety (no excess of bleeding events).➢ Phase II trials are designed to generate signals of safety and efficacy and to select the dose or doses for phase III pivotal trials. However, phase II data ...
Voir la vidéo
Conférences

le (8m8s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Christophe GAUDIN)

MODIGLIANI Workshop 1 - Friday November 30, 2012 :THE THROMBOSIS TRIALISTS WORKSHOPDOSE AND TARGET PATIENT POPULATIONS ISSUESChairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN, Bucharest, ROMWebcast: Johanne SILVAIN, Paris, FRAThe development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety (no excess of bleeding events).➢ Phase II trials are designed to generate signals of safety and efficacy and to select the dose or doses for phase III pivotal trials. However, phase II data ...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte